following a full submission:
quizartinib (Vanflyta®) is accepted for use within NHSScotland.
Indication under review: in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3-ITD positive.
In a randomised, double-blind, phase III study, the addition of quizartinib compared with placebo to standard chemotherapy significantly improved overall survival in newly diagnosed patients with AML with FLT3-ITD mutation.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- quizartinib (Vanflyta)
- SMC ID:
- SMC2699
- Indication:
In combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) positive.
- Pharmaceutical company
- Daiichi Sankyo UK Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 11 November 2024